Effects of protein and electrical stimulation on muscle mass in elderly hospitalized patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how protein supplementation combined with neuromuscular electrical stimulation can affect muscle mass, hospital stay duration, readmission rates, and mortality in elderly patients. The focus is on hospitalized individuals who often experience malnutrition and muscle wasting due to inactivity and inflammation. Participants will receive either the protein and stimulation intervention or a placebo and sham stimulation to assess the effectiveness of the treatment. The study aims to provide insights into improving outcomes for elderly patients during hospitalization.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* both sex;
* 65 years and older;
* hospital stay less than 48 hours;

Exclusion Criteria:

* cancer in the last 5 years;
* delirium;
* cognitive deficit that impossibility the patient to read and sign the informed consent form;
* neurological disease;
* neurodegenerative muscular disease;
* impossibility to receive the intervention.

Where it's running

• University of Sao Paulo
  São Paulo, Brazil Recruiting

Study contacts

• Principal investigator: Hamilton Roschel, PhD — University of Sao Paulo General Hospital
• Study coordinator: Hamilton Roschel, PhD
• Email: hars@usp.br
• Phone: +551130618789

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Examining food intake in hospitalized elderly and its effects on muscle and health outcomes

  This study looks at how much food elderly patients eat while in the hospital and how it affects their muscle strength and overall health after they go home.

  Recruiting University of Sao Paulo General Hospital · São Paulo, São Paulo · NCT06940284

• Pregnancy-time treatment of fetal SMA: a registry of mother-child outcomes

  This registry collects information on pregnancies where a fetus diagnosed with spinal muscular atrophy was treated with a disease‑modifying therapy in the womb to see how the pregnancy and baby fare after birth.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07805278

• Intrathecal Zolgensma in spinal muscular atrophy patients in Japan

  This study tests the safety and real‑world effectiveness of intrathecal onasemnogene abeparvovec in SMA patients in Japan.

  Recruiting at 4 sites Novartis · Toyoake, Aichi-ken and 3 other locations · NCT07767890

• Spinal muscular atrophy patients get a single intrathecal gene therapy dose to see how it works in real-world U.S. settings

  This study tests whether a one-time intrathecal dose of ITVISMA® (onasemnogene abeparvovec-brve) is safe and effective for SMA patients in real-world U.S. clinical practice.

  Recruiting at 6 sites Phase 4 Novartis · Little Rock, Arkansas and 5 other locations · NCT07448610

• Salanersen (BIIB115) for improving movement in people 15–60 with spinal muscular atrophy who are treatment‑naïve or previously on risdiplam

  This trial tests whether salanersen helps movement and is safe for people aged 15 to 60 with spinal muscular atrophy who are either new to treatment or have taken risdiplam.

  Recruiting at 3 sites Phase 3 Biogen · Palo Alto, California and 2 other locations · NCT07444476

• CuidAME: Spain's longitudinal registry for spinal muscular atrophy

  This project collects long-term clinical and treatment data from children and adults with genetically confirmed 5q spinal muscular atrophy in Spain to track outcomes over time.

  Recruiting Fundació Sant Joan de Déu · Esplugues de Llobregat · NCT07231549

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.